Cargando…
Prognostic value of translocation 11;14 in patients with relapsed/refractory myeloma receiving anti-CD38 therapy
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9758218/ https://www.ncbi.nlm.nih.gov/pubmed/36526617 http://dx.doi.org/10.1038/s41408-022-00769-4 |
| _version_ | 1784851995308326912 |
|---|---|
| author | Mohyuddin, Ghulam Rehman Chakraborty, Rajshekhar Calip, Gregory S. Ascha, Mustafa S. Wang, Xiaoliang Rubinstein, Samuel M. Tuchman, Sascha Costa, Luciano Haaland, Benjamin Giri, Smith Mian, Hira Fonseca, Rafael Sborov, Douglas |
| author_facet | Mohyuddin, Ghulam Rehman Chakraborty, Rajshekhar Calip, Gregory S. Ascha, Mustafa S. Wang, Xiaoliang Rubinstein, Samuel M. Tuchman, Sascha Costa, Luciano Haaland, Benjamin Giri, Smith Mian, Hira Fonseca, Rafael Sborov, Douglas |
| author_sort | Mohyuddin, Ghulam Rehman |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9758218 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-97582182022-12-18 Prognostic value of translocation 11;14 in patients with relapsed/refractory myeloma receiving anti-CD38 therapy Mohyuddin, Ghulam Rehman Chakraborty, Rajshekhar Calip, Gregory S. Ascha, Mustafa S. Wang, Xiaoliang Rubinstein, Samuel M. Tuchman, Sascha Costa, Luciano Haaland, Benjamin Giri, Smith Mian, Hira Fonseca, Rafael Sborov, Douglas Blood Cancer J Correspondence Nature Publishing Group UK 2022-12-16 /pmc/articles/PMC9758218/ /pubmed/36526617 http://dx.doi.org/10.1038/s41408-022-00769-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Correspondence Mohyuddin, Ghulam Rehman Chakraborty, Rajshekhar Calip, Gregory S. Ascha, Mustafa S. Wang, Xiaoliang Rubinstein, Samuel M. Tuchman, Sascha Costa, Luciano Haaland, Benjamin Giri, Smith Mian, Hira Fonseca, Rafael Sborov, Douglas Prognostic value of translocation 11;14 in patients with relapsed/refractory myeloma receiving anti-CD38 therapy |
| title | Prognostic value of translocation 11;14 in patients with relapsed/refractory myeloma receiving anti-CD38 therapy |
| title_full | Prognostic value of translocation 11;14 in patients with relapsed/refractory myeloma receiving anti-CD38 therapy |
| title_fullStr | Prognostic value of translocation 11;14 in patients with relapsed/refractory myeloma receiving anti-CD38 therapy |
| title_full_unstemmed | Prognostic value of translocation 11;14 in patients with relapsed/refractory myeloma receiving anti-CD38 therapy |
| title_short | Prognostic value of translocation 11;14 in patients with relapsed/refractory myeloma receiving anti-CD38 therapy |
| title_sort | prognostic value of translocation 11;14 in patients with relapsed/refractory myeloma receiving anti-cd38 therapy |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9758218/ https://www.ncbi.nlm.nih.gov/pubmed/36526617 http://dx.doi.org/10.1038/s41408-022-00769-4 |
| work_keys_str_mv | AT mohyuddinghulamrehman prognosticvalueoftranslocation1114inpatientswithrelapsedrefractorymyelomareceivinganticd38therapy AT chakrabortyrajshekhar prognosticvalueoftranslocation1114inpatientswithrelapsedrefractorymyelomareceivinganticd38therapy AT calipgregorys prognosticvalueoftranslocation1114inpatientswithrelapsedrefractorymyelomareceivinganticd38therapy AT aschamustafas prognosticvalueoftranslocation1114inpatientswithrelapsedrefractorymyelomareceivinganticd38therapy AT wangxiaoliang prognosticvalueoftranslocation1114inpatientswithrelapsedrefractorymyelomareceivinganticd38therapy AT rubinsteinsamuelm prognosticvalueoftranslocation1114inpatientswithrelapsedrefractorymyelomareceivinganticd38therapy AT tuchmansascha prognosticvalueoftranslocation1114inpatientswithrelapsedrefractorymyelomareceivinganticd38therapy AT costaluciano prognosticvalueoftranslocation1114inpatientswithrelapsedrefractorymyelomareceivinganticd38therapy AT haalandbenjamin prognosticvalueoftranslocation1114inpatientswithrelapsedrefractorymyelomareceivinganticd38therapy AT girismith prognosticvalueoftranslocation1114inpatientswithrelapsedrefractorymyelomareceivinganticd38therapy AT mianhira prognosticvalueoftranslocation1114inpatientswithrelapsedrefractorymyelomareceivinganticd38therapy AT fonsecarafael prognosticvalueoftranslocation1114inpatientswithrelapsedrefractorymyelomareceivinganticd38therapy AT sborovdouglas prognosticvalueoftranslocation1114inpatientswithrelapsedrefractorymyelomareceivinganticd38therapy |